
Mangalam Drugs and Organics Ltd is Rated Strong Sell
2026-06-05 10:10:20Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 08 June 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall market standing.
Read full news article
Mangalam Drugs and Organics Ltd is Rated Strong Sell
2026-05-20 10:10:21Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 May 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 20 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.
Read full news article
Mangalam Drugs and Organics Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight
2026-05-18 10:00:06At Rs 28.46, sellers were still queuing — but there were no buyers willing to take the other side. Mangalam Drugs and Organics Ltd locked at its lower circuit of 5% on 18 May 2026, with unfilled sell orders and a frozen price.
Read full news articleAre Mangalam Drugs and Organics Ltd latest results good or bad?
2026-05-16 19:21:27The latest financial results for Mangalam Drugs and Organics Ltd reveal significant operational challenges. In Q4 FY26, the company reported net sales of ₹67.29 crores, reflecting a quarter-on-quarter growth of 15.26% from ₹58.38 crores in Q3 FY26. However, this figure represents a year-on-year decline of 7.54%, indicating ongoing demand issues. The net profit for the same quarter was a loss of ₹13.42 crores, marking a substantial deterioration compared to the previous year. The operating margin for Q4 FY26 fell to -8.35%, a stark contrast to the positive margin of 13.60% reported in Q4 FY25. This collapse in profitability is further underscored by the operating profit before depreciation, interest, tax, and other income (PBDIT excluding OI), which resulted in a loss of ₹5.62 crores, compared to a profit of ₹9.90 crores in the same quarter last year. For the full fiscal year FY25, Mangalam Drugs recorded ...
Read full news article
Mangalam Drugs Q4 FY26: Mounting Losses Signal Deepening Operational Crisis
2026-05-15 18:00:33Mangalam Drugs and Organics Ltd. reported a devastating fourth quarter for FY26, with net losses widening to ₹13.42 crores—marking a staggering 22,466.67% year-on-year deterioration from a marginal profit of ₹0.06 crores in Q4 FY25. The micro-cap pharmaceutical company, with a market capitalisation of just ₹48.00 crores, saw its stock languish at ₹30.01 on May 15, down 62.74% over the past year and trading 68.34% below its 52-week high of ₹94.80.
Read full news articleWhen is the next results date for Mangalam Drugs and Organics Ltd?
2026-05-07 23:16:40The next results date for Mangalam Drugs and Organics Ltd is scheduled for 14 May 2026....
Read full news article
Mangalam Drugs and Organics Ltd is Rated Strong Sell
2026-04-27 10:10:25Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 27 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.
Read full news article
Mangalam Drugs and Organics Ltd is Rated Strong Sell
2026-04-13 10:10:14Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 13 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.
Read full news article
Mangalam Drugs and Organics Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent
2026-04-08 10:00:08At Rs 31.57, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Mangalam Drugs and Organics Ltd locked at its upper circuit of 4.99% on 8 Apr 2026, with buyers queuing and no sellers willing to part with shares.
Read full news articleCompliances-Reg.24(A)-Annual Secretarial Compliance
25-May-2026 | Source : BSEAnnual Secretarial Compliance Report to be filed for the financial year ended March 31 2026 as per Regulation 24A of SEBI LODR 2025.
Compliances-Reg.24(A)-Annual Secretarial Compliance
25-May-2026 | Source : BSESubmission of Annual Secretarial Compliance Report for the period ended 31st March 2026
Announcement under Regulation 30 (LODR)-Newspaper Publication
19-May-2026 | Source : BSEDisclosure under Regulation 30 of LODR 2015 for newspaper publication regarding the dispatch of Postal Ballot/ E- Voting seeking shareholders approval.
Corporate Actions
No Upcoming Board Meetings
Mangalam Drugs and Organics Ltd has declared 5% dividend, ex-date: 21 Dec 17
No Splits history available
No Bonus history available
No Rights history available






